Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

Sergio Bertoglio, Angelo Benevento, Pierluigi Percivale, Ferdinando Cafiero, Luciano Moresco, Alberto Peressini, Renzo Dionigi, Fausto Badellino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Radioimmunoguided surgery (RIGS) with radiolabeled monoclonal antibodies (MoAbs) has been reported as useful in second-look colorectal cancer procedures to improve surgical decision-making by helping avoid needless extensive surgery and expanding curative resection to sites of recurrence that have been missed previously. Sixteen asymptomatic patients with an history of colorectal cancer surgery underwent second-look surgery using the RIGS system, solely on the basis of rising serum levels of carcinoembryonic antigen (CEA). All patients were injected preoperatively with the anti- tumor-associated glycoprotein (TAG) 125I-labeled MoAb B72.3. Both traditional and RIGS exploration were used to determine the extension of a possible recurrence and its resectability for cure. Recurrent disease was observed in 14 of the 16 patients as the result of this combined exploration. Exploration alone showed the presence of recurrent disease in 9 of 16 patients (56.2%). Thus, RIGS found overlooked tumor in five patients (31.2%). All the additional RIGS-detected tumor sites were locoregional recurrences resectable for cure; conversely, no diagnostic improvements were shown in patients with liver metastases. Resection for cure was obtained by this approach in 9 of 16 patients (56.2%). Two patients without disease at the exploratory laparotomy recurred within 2 months at sites away from the abdomen. RIGS improved the results of colorectal cancer CEA-guided second- look procedures in asymptomatic patients by recruiting one-third of patients to curative resections.

Original languageEnglish
Pages (from-to)263-267
Number of pages5
JournalSeminars in Surgical Oncology
Volume15
Issue number4
DOIs
Publication statusPublished - 1998

Fingerprint

Second-Look Surgery
Carcinoembryonic Antigen
Colorectal Neoplasms
Recurrence
Neoplasms
Colorectal Surgery
Abdomen
Laparotomy
Decision Making
Glycoproteins

Keywords

  • Adenocarcinoma
  • Carcinoembryonic antigen
  • Colonic neoplasms
  • Colorectal neoplasms
  • Intraoperative period
  • Iodine radioisotopes
  • Local neoplasm recurrence
  • Monoclonal antibodies
  • Neoplasm metastasis
  • Neoplasm staging
  • Patient selection
  • Radioimmunodetection
  • Rectal neoplasms
  • Reoperation

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer. / Bertoglio, Sergio; Benevento, Angelo; Percivale, Pierluigi; Cafiero, Ferdinando; Moresco, Luciano; Peressini, Alberto; Dionigi, Renzo; Badellino, Fausto.

In: Seminars in Surgical Oncology, Vol. 15, No. 4, 1998, p. 263-267.

Research output: Contribution to journalArticle

Bertoglio, Sergio ; Benevento, Angelo ; Percivale, Pierluigi ; Cafiero, Ferdinando ; Moresco, Luciano ; Peressini, Alberto ; Dionigi, Renzo ; Badellino, Fausto. / Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer. In: Seminars in Surgical Oncology. 1998 ; Vol. 15, No. 4. pp. 263-267.
@article{c24454bb45b949cba2fe4d54df4cf8b1,
title = "Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer",
abstract = "Radioimmunoguided surgery (RIGS) with radiolabeled monoclonal antibodies (MoAbs) has been reported as useful in second-look colorectal cancer procedures to improve surgical decision-making by helping avoid needless extensive surgery and expanding curative resection to sites of recurrence that have been missed previously. Sixteen asymptomatic patients with an history of colorectal cancer surgery underwent second-look surgery using the RIGS system, solely on the basis of rising serum levels of carcinoembryonic antigen (CEA). All patients were injected preoperatively with the anti- tumor-associated glycoprotein (TAG) 125I-labeled MoAb B72.3. Both traditional and RIGS exploration were used to determine the extension of a possible recurrence and its resectability for cure. Recurrent disease was observed in 14 of the 16 patients as the result of this combined exploration. Exploration alone showed the presence of recurrent disease in 9 of 16 patients (56.2{\%}). Thus, RIGS found overlooked tumor in five patients (31.2{\%}). All the additional RIGS-detected tumor sites were locoregional recurrences resectable for cure; conversely, no diagnostic improvements were shown in patients with liver metastases. Resection for cure was obtained by this approach in 9 of 16 patients (56.2{\%}). Two patients without disease at the exploratory laparotomy recurred within 2 months at sites away from the abdomen. RIGS improved the results of colorectal cancer CEA-guided second- look procedures in asymptomatic patients by recruiting one-third of patients to curative resections.",
keywords = "Adenocarcinoma, Carcinoembryonic antigen, Colonic neoplasms, Colorectal neoplasms, Intraoperative period, Iodine radioisotopes, Local neoplasm recurrence, Monoclonal antibodies, Neoplasm metastasis, Neoplasm staging, Patient selection, Radioimmunodetection, Rectal neoplasms, Reoperation",
author = "Sergio Bertoglio and Angelo Benevento and Pierluigi Percivale and Ferdinando Cafiero and Luciano Moresco and Alberto Peressini and Renzo Dionigi and Fausto Badellino",
year = "1998",
doi = "10.1002/(SICI)1098-2388(199812)15:4<263::AID-SSU15>3.0.CO;2-Q",
language = "English",
volume = "15",
pages = "263--267",
journal = "Seminars in Surgical Oncology",
issn = "8756-0437",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

AU - Bertoglio, Sergio

AU - Benevento, Angelo

AU - Percivale, Pierluigi

AU - Cafiero, Ferdinando

AU - Moresco, Luciano

AU - Peressini, Alberto

AU - Dionigi, Renzo

AU - Badellino, Fausto

PY - 1998

Y1 - 1998

N2 - Radioimmunoguided surgery (RIGS) with radiolabeled monoclonal antibodies (MoAbs) has been reported as useful in second-look colorectal cancer procedures to improve surgical decision-making by helping avoid needless extensive surgery and expanding curative resection to sites of recurrence that have been missed previously. Sixteen asymptomatic patients with an history of colorectal cancer surgery underwent second-look surgery using the RIGS system, solely on the basis of rising serum levels of carcinoembryonic antigen (CEA). All patients were injected preoperatively with the anti- tumor-associated glycoprotein (TAG) 125I-labeled MoAb B72.3. Both traditional and RIGS exploration were used to determine the extension of a possible recurrence and its resectability for cure. Recurrent disease was observed in 14 of the 16 patients as the result of this combined exploration. Exploration alone showed the presence of recurrent disease in 9 of 16 patients (56.2%). Thus, RIGS found overlooked tumor in five patients (31.2%). All the additional RIGS-detected tumor sites were locoregional recurrences resectable for cure; conversely, no diagnostic improvements were shown in patients with liver metastases. Resection for cure was obtained by this approach in 9 of 16 patients (56.2%). Two patients without disease at the exploratory laparotomy recurred within 2 months at sites away from the abdomen. RIGS improved the results of colorectal cancer CEA-guided second- look procedures in asymptomatic patients by recruiting one-third of patients to curative resections.

AB - Radioimmunoguided surgery (RIGS) with radiolabeled monoclonal antibodies (MoAbs) has been reported as useful in second-look colorectal cancer procedures to improve surgical decision-making by helping avoid needless extensive surgery and expanding curative resection to sites of recurrence that have been missed previously. Sixteen asymptomatic patients with an history of colorectal cancer surgery underwent second-look surgery using the RIGS system, solely on the basis of rising serum levels of carcinoembryonic antigen (CEA). All patients were injected preoperatively with the anti- tumor-associated glycoprotein (TAG) 125I-labeled MoAb B72.3. Both traditional and RIGS exploration were used to determine the extension of a possible recurrence and its resectability for cure. Recurrent disease was observed in 14 of the 16 patients as the result of this combined exploration. Exploration alone showed the presence of recurrent disease in 9 of 16 patients (56.2%). Thus, RIGS found overlooked tumor in five patients (31.2%). All the additional RIGS-detected tumor sites were locoregional recurrences resectable for cure; conversely, no diagnostic improvements were shown in patients with liver metastases. Resection for cure was obtained by this approach in 9 of 16 patients (56.2%). Two patients without disease at the exploratory laparotomy recurred within 2 months at sites away from the abdomen. RIGS improved the results of colorectal cancer CEA-guided second- look procedures in asymptomatic patients by recruiting one-third of patients to curative resections.

KW - Adenocarcinoma

KW - Carcinoembryonic antigen

KW - Colonic neoplasms

KW - Colorectal neoplasms

KW - Intraoperative period

KW - Iodine radioisotopes

KW - Local neoplasm recurrence

KW - Monoclonal antibodies

KW - Neoplasm metastasis

KW - Neoplasm staging

KW - Patient selection

KW - Radioimmunodetection

KW - Rectal neoplasms

KW - Reoperation

UR - http://www.scopus.com/inward/record.url?scp=0031789779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031789779&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2388(199812)15:4<263::AID-SSU15>3.0.CO;2-Q

DO - 10.1002/(SICI)1098-2388(199812)15:4<263::AID-SSU15>3.0.CO;2-Q

M3 - Article

C2 - 9829384

AN - SCOPUS:0031789779

VL - 15

SP - 263

EP - 267

JO - Seminars in Surgical Oncology

JF - Seminars in Surgical Oncology

SN - 8756-0437

IS - 4

ER -